Abstract:Neisseria meningitidis serogroup B (MenB) is the leading cause of meningococcal meningitis and sepsis in industrialized countries, with the highest incidence in infants and adolescents. Two recombinant protein vaccines that protect against MenB are now available (i.e. 4CMenB and MenB-fHbp). Both vaccines contain the Factor H Binding Protein (fHbp) antigen, which can bind the Human Factor H (fH), the main negative regulator of the alternative complement pathway, thus enabling bacterial survival in the blood. fHbp is present in meningococcal strains as three main variants which are immunologically distinct. Here we sought to obtain detailed information about the epitopes targeted by anti-fHbp antibodies induced by immunization with the 4CMenB multicomponent vaccine. Thirteen anti-fHbp human monoclonal antibodies (mAbs) were identified in a library of over 100 antibody fragments (Fabs) obtained from three healthy adult volunteers immunized with 4CMenB. Herein, the key cross-reactive mAbs were further characterized for antigen binding affinity, complement-mediated serum bactericidal activity (SBA) and the ability to inhibit binding of fH to live bacteria. For the first time, we identified a subset of anti-fHbp mAbs able to elicit human SBA against strains with all three variants and able to compete with human fH for fHbp binding. We present the crystal structure of fHbp v1.1 complexed with human antibody 4B3. The structure, combined with mutagenesis and binding studies, revealed the critical cross-reactive epitope. The structure also provided the molecular basis of competition for fH binding. These data suggest that the fH binding site on fHbp v1.1 can be accessible to the human immune system upon immunization, enabling elicitation of human mAbs broadly protective against MenB. The novel structural, biochemical and functional data are of great significance because the human vaccine-elicited mAbs are the first reported to inhibit the binding of fH to fHbp, and are bactericidal with human complement. Our studies provide molecular insights into the human immune response to the 4CMenB meningococcal vaccine and fuel the rationale for combined structural, immunological and functional studies when seeking deeper understanding of the mechanisms of action of human vaccines.

Expression and Immunological Analysis of Recombinant Nesseria Meningitis Group B Recombinant fHBP Fusion Protein

Role of Factor H Binding Protein in Neisseria Meningitidis Virulence and Its Potential As a Vaccine Candidate to Broadly Protect Against Meningococcal Disease

Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen

Characterisation and Immunogenicity of Neisseria cinerea outer membrane vesicles displaying NadA, NHBA and fHbp from Neisseria meningitidis serogroup B

Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor H

The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement

4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp

Extensive Genetic Diversity and Epidemiological Patterns of Factor H-Binding Protein Variants among Neisseria meningitidis in China

Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China

Factor H binding protein (FHbp): An evaluation of genotypic diversity across Neisseria meningitidis serogroups

Factor H binding protein (fHbp)-mediated differential complement resistance of a serogroup C Neisseria meningitidis isolate from cerebrospinal fluid of a patient with invasive meningococcal disease

Meningococcal factor H-binding protein: implications for disease susceptibility, virulence, and vaccines

Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing Neisseria meningitidis strain coverage by meningococcal vaccines

Over-expression of fHbp in Arabdopsis for development of meningococcal serogroup B subunit vaccine

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine

Construction and assessment of the immunogenicity and bactericidal activity of fusion protein porin A from Neisseria meningitidis serogroups A and B admixed with OMV adjuvant as a novel vaccine candidate

Protective Antimicrobial Effect of the Potential Vaccine Created on the Basis of the Structure of the IgA1 Protease from Neisseria meningitidis

[Study on the Bactericidal Antibody Against Neisseria Meningitidis Serogroup C Strains after Immunization with a Divalent Polysaccharide (A Plus C) Vaccine].

An Integrated in Silico Approach for the Identification of Novel Potential Drug Target and Chimeric Vaccine Against Neisseria Meningitides Strain 331401 Serogroup X by Subtractive Genomics and Reverse Vaccinology

Development of A Time-Resolved Fluoroimmunoassay of Cfp-10 for Rapid Diagnosis of Tuberculous Pleural Effusion